18 recruiting, 14 active not recruiting, 8 completed, 5 terminated. 42 Phase 2, 18 Phase 1, 5 Phase 3, 1 Early Phase 1.
Follow tafasitamab: new trials by email Literature Review of tafasitamab trials Research Report on tafasitamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide Orelabrutinib, Tafasitamab, Lenalidomide - Follicular Lymphoma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 27 | 2026-04-15 | 2026-05-14 |
| A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma Epcoritamab, Lenalidomide, Tafasitamab - Lymphoma | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2025-08-13 | 2026-04-07 | |
| HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL Tafasitamab, Rituximab, Lenalidomide - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 65 | 2025-08-07 | 2026-08-12 |
| Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma Epcoritamab, Epcoritamab, tafasitamab and lenalidomide - Large B Cell Lymphoma | Phase 2 | Recruiting | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 80 | 2025-08-04 | 2026-09-29 |
| Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym Tafasitamab, Lenalidomide - Large B-cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 28 | 2025-03-19 | 2026-04-03 |
| Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL Tafasitamab, Lenalidomide, Rituximab - Non-Hodgkin Lymphoma | Phase 2 | Recruiting | University of Cologne | 20 | 2024-08-23 | 2025-08-13 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders Tafasitamab, Fludarabine phosphate, Cyclophosphamide - Autoimmune Disorders, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 47 | 2024-07-31 | 2026-10-06 |
| Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Tafasitamab, Lenalidomide, Gemcitabine - DLBCL | Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 244 | 2024-05-07 | 2024-07-25 |
| Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma Zanubrutinib, Tafasitamab - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Alvaro Alencar, MD | 27 | 2024-05-03 | 2026-09-21 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 100 | 2024-01-04 | 2024-11-18 |
| Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 27 | 2023-10-02 | 2025-11-06 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2026-10-28 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL Tafasitamab Injection - Diffuse Large B-cell Lymphoma | Unknown | Zhao Weili | 15 | 2023-07-01 | 2023-06-01 | |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
Showing 20 of 55. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (20) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Lymphoma, B-Cell (6) · Lymphoma, Non-Hodgkin (6) · Recurrence (6) · Lymphoma (5) · Lymphoma, Follicular (5) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Mantle-Cell (4) · Bronchiolitis Obliterans Syndrome (2) · Burkitt Lymphoma (2) · Hematologic Neoplasms (2) · Autoimmune Diseases (1) · Graft vs Host Disease (1) · Hematologic Diseases (1)
Incyte Corporation (8) · MorphoSys AG (6) · City of Hope Medical Center (3) · M.D. Anderson Cancer Center (3) · University of Washington (3) · Beijing InnoCare Pharma Tech Co., Ltd. (2) · Celgene (2) · Memorial Sloan Kettering Cancer Center (2) · Xencor, Inc. (2) · Academic and Community Cancer Research United (1) · Alvaro Alencar, MD (1) · Brown University (1) · Canadian Cancer Trials Group (1) · David Bond, MD (1) · Epizyme, Inc. (1)
United States (40) · Spain (13) · Italy (12) · France (11) · Austria (10) · Germany (10) · Belgium (8) · Poland (8) · South Korea (8) · United Kingdom (8) · Czechia (7) · Hungary (7) · Israel (6) · Canada (5) · China (5)
Oliver Manzke, MD (2) · Adam Olszewski (1) · Alvaro Alencar, MD (1) · Amandeep Salhotra (1) · Anastasios Stathis, MD (1) · Anita Kumar, MD (1) · Anke Muth (1) · Benjamin M Heyman (1) · Chitra Hosing, MD (1) · David A Bond, MD (1) · Davide Rossi, MD (1) · Diego Villa (1) · Elias Jabbour, MD (1)
PMID 39319495, PMID 37369099, PMID 25301708, PMID 29444231, PMID 32511983, PMID 34196165, PMID 34343354, PMID 34414843, PMID 34433649, PMID 34779360, PMID 35674661, PMID 35861632, PMID 35952327, PMID 37646664, PMID 40802906, PMID 40993016, PMID 41176775, PMID 41360064, PMID 41563911, PMID 42217458, PMID 42255257
2023 (3), P30CA033572 (3), 2014 (2), 2018 (1), 2019 (1), P30CA015083 (1), U10CA180888 (1)